Blood test may help tailor breast cancer treatment
NCT ID NCT05333874
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This pilot study is testing whether a personalized blood test that looks for leftover tumor DNA can help doctors make better treatment decisions for people with early-stage breast cancer. About 34 participants with triple-negative or HER2-positive breast cancer will receive chemotherapy before surgery, then have their blood tested after surgery. If the test finds cancer DNA, patients may choose to change their follow-up treatment. The goal is to see if this approach improves outcomes and reduces unnecessary treatments.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Neoadjuvant chemotherapy and a personalized blood test (Signatera) that detects tumor DNA in the blood
- What this could lead to
- If successful, this could help doctors decide whether more or less treatment is needed after surgery, potentially reducing unnecessary side effects.
- What could go wrong
- This is a very early pilot study with only 34 participants, so results may not apply to everyone. The blood test is still experimental and may not always be accurate.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER, EARLY-ONSET are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cooperman Barnabas Medical Center
Livingston, New Jersey, 07052, United States
-
Jersey City Medical Center
Jersey City, New Jersey, 07302, United States
-
Monmouth Medical Center
Long Branch, New Jersey, 07740, United States
-
Monmouth Medical Center - Southern Campus
Lakewood, New Jersey, 08701, United States
-
Monmouth Medical Center Vantage Point Infusion Cente
West Long Branch, New Jersey, 07746, United States
-
Newark Beth Israel Medical Center
Newark, New Jersey, 07112, United States
-
RWJBarnabas Health - Robert Wood Johnson University Hospital
Hamilton, New Jersey, 08690, United States
-
Robert Wood Johnson Barnabas Hospital -Somerset
Somerville, New Jersey, 08876, United States
-
Robert Wood Johnson University Hospital
New Brunswick, New Jersey, 08901, United States
-
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey, 08903, United States
-
Steeplechase Cancer Center
Somerville, New Jersey, 08876, United States
-
Trinitas Hospital and Comprehensive Cancer Center
Elizabeth, New Jersey, 07202, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug outsmart resistant breast cancer?
- Can a new targeted drug outperform the current standard for HER2-Positive breast cancer?
- Chemo-Free hope: new pill combo targets Hard-to-Treat breast cancer
- Could a simple blood test let some breast cancer patients stop treatment?
- New drug cocktail aims to outsmart resistant breast cancer
- Blood test may predict breast cancer treatment success